UoOxford Confidence in Concept 2013

Lead Research Organisation: University of Oxford

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding.  It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.

Publications

10 25 50
 
Description -VaxCelerate: Development of a T Cell-Based Vaccine for Q Fever
Amount $163,000 (USD)
Organisation Massachusetts General Hospital 
Sector Hospitals
Country United States
Start 08/2018 
End 07/2019
 
Description ARUK pilot grant
Amount £46,738 (GBP)
Funding ID ARUK-PPG2017A-19 
Organisation Versus Arthritis 
Start 05/2017 
End 05/2018
 
Description Centres of Excellence in Neurodegeneration
Amount £250,683 (GBP)
Funding ID 1509HM013/NF2 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 05/2016 
End 04/2018
 
Description Confidence in Concept 3
Amount £17,849 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 06/2016 
End 08/2016
 
Description Confidence in concept Oxford
Amount £45,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 10/2017 
End 06/2018
 
Description Development Pathway Funding Scheme
Amount £546,210 (GBP)
Funding ID MR/R006423/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 05/2018 
End 04/2021
 
Description Development of a novel vaccine to protect against Q fever epidemics: late stage preclinical formulation and progression to clinical trial
Amount £1,000,000 (GBP)
Funding ID 971619 
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 09/2018 
End 08/2020
 
Description Developmental Pathway Funding Scheme
Amount £2,187,000 (GBP)
Organisation MRC Biomedical Catalyst Developmental Pathway Funding Scheme (DPFS) 
Sector Public
Country United Kingdom
Start 04/2017 
End 04/2021
 
Description Jenner Institute Investigator
Amount £3,000 (GBP)
Organisation University of Oxford 
Department Jenner Institute
Sector Academic/University
Country United Kingdom
Start 01/2017 
End 12/2017
 
Description Jenner Institute Investigator
Amount £3,000 (GBP)
Organisation University of Oxford 
Department Jenner Institute
Sector Academic/University
Country United Kingdom
Start 01/2018 
End 12/2018
 
Description Jenner Institute Investigator
Amount £3,000 (GBP)
Organisation University of Oxford 
Department Jenner Institute
Sector Academic/University
Country United Kingdom
Start 01/2015 
End 12/2015
 
Description Jenner Institute Investigator
Amount £3,000 (GBP)
Organisation University of Oxford 
Department Jenner Institute
Sector Academic/University
Country United Kingdom
Start 01/2019 
End 12/2019
 
Description Jenner Institute Investigator
Amount £3,000 (GBP)
Organisation University of Oxford 
Department Jenner Institute
Sector Academic/University
Country United Kingdom
Start 01/2016 
End 12/2016
 
Description MND Association PhD Studentship
Amount £96,252 (GBP)
Organisation Motor Neurone Disease Association (MND) 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2016 
End 09/2019
 
Description MRC CRI: The Oxford Single Cell Biology Consortium (co-investigator)
Amount £4,975,434 (GBP)
Funding ID MR/M00919X/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 04/2015 
End 04/2016
 
Description MRC DPFS
Amount £2,711,781 (GBP)
Funding ID MR/N019067/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 07/2016 
End 07/2020
 
Description MRC Discovery Award (co-investigator)
Amount £1,000,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 04/2016 
End 04/2019
 
Description MRC Discovery Award - Identification and characterisation of cellular targets for genome editing of foetal haematopoietic stem/progenitor cells
Amount £56,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 09/2016 
End 08/2017
 
Description MRC Proximity to discovery Industry Engagement Fund
Amount £10,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 02/2016 
End 07/2016
 
Description New vaccines for global epidemics (Plague)
Amount £100,000 (GBP)
Funding ID 972228 
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 09/2016 
End 09/2017
 
Description Programme Grant Renewal
Amount £1,700,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 04/2016 
End 04/2021
 
Description Proof of Concept
Amount £111,924 (GBP)
Funding ID 641317 
Organisation European Research Council (ERC) 
Sector Public
Country European Union (EU)
Start 03/2015 
End 09/2016
 
Description Rosetrees Trust
Amount £40,000 (GBP)
Organisation Rosetrees Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2015 
End 01/2017
 
Description SBRI
Amount £360,000 (GBP)
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 10/2016 
End 09/2017
 
Description SBRI Vaccines against outbreak diseases
Amount £3,000,000 (GBP)
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 10/2017 
End 09/2020
 
Description Senior Investigator Award
Amount £2,262,504 (GBP)
Funding ID 104633/Z/14/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2015 
End 02/2021
 
Description Stanley Medical Research Institute treatment trials
Amount $284,176 (USD)
Organisation Stanley Medical Research Institute (SMRI) 
Sector Charity/Non Profit
Country Global
Start 07/2015 
End 07/2016
 
Description UCSF
Amount £36,000 (GBP)
Organisation University of Oxford 
Department Oxford University Innovation
Sector Private
Country United Kingdom
Start 11/2017 
End 02/2019
 
Description Wellcome Trust ISSF
Amount £150,135 (GBP)
Organisation Wellcome Trust 
Department Wellcome Trust Institutional Strategic Support Fund
Sector Charity/Non Profit
Country United Kingdom
Start 11/2014 
End 11/2017
 
Description vaccines for global epidemics - preclinical (Q fever)
Amount £100,000 (GBP)
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 12/2017 
End 04/2018
 
Title Bayesian modelling of slow wave activity saturation 
Description SWAS is an electrophysiological phenomenon that occurs under general anaesthesia. Our functional magnetic resonance imaging data suggest that at SWAS in an individual loses perception of incoming external stimuli. We developed Bayesian methods to characterise slow wave activity saturation (SWAS) in electroencephalography (EEG) data in off-line and real-time modes as there is significant translational potential for SWAS-based depth of anaesthesia monitoring. 
Type Of Material Model of mechanisms or symptoms - human 
Provided To Others? No  
Impact This is the first development step towards adaptive, smart and individualised depth of anaesthesia monitoring based on SWAS. This monitor will potentially help anaesthetists deliver the optimum anaesthetic dose and reduce the deleterious consequences of under- and over-anaesthesia. We have filed a patent based on perception loss at SWAS that includes this Bayesian modelling. 
 
Title Biosignatures in brain tissue 
Description A novel method for differentiation of neuropsychiatric conditions based on the identification and modelling of signature patterns of microstructural change in the organisation of the cerebral cortex 
Type Of Material Model of mechanisms or symptoms - human 
Provided To Others? No  
Impact This method forms part of a patent which has been filed. 
 
Title Evaluation of in vitro antigen expression as a correlate of immunogenicity 
Description We have developed an in vitro assay intending to measure antigen expression achieved in cell lines after infection by viral vectored vaccine candidate, in order to replace some of the mouse immunogenicity studies. The number of vaccine candidate developed with modifications, for example of the promoter, signal sequences or vector backbone, is high, and implies that a lot of mice are used to compare the immunogenicity of these vaccines. We believe that this approach could be refined, by measuring the level of antigen expressed by each vaccine in mice and human cells. We hypothesise that the level of antigen expression is a main driver of immunogenicity (albeit not the only one). Therefore screening of new vectors can be performed in cells rather than in animal experiment, in particular in the case of comparing vector backbones, as this is more likely to influence immunogenicity in a specie-specific manner. Therefore screening in cells, in particular human cells rather than mouse is highly relevant. 
Type Of Material Model of mechanisms or symptoms - in vitro 
Year Produced 2015 
Provided To Others? Yes  
Impact In our group this technology has allowed understanding of mechanisms driving antigen expression fro viral vaccine candidates, as well as selection of vectors with optimal antigen expression for further testing in in vivo experiments. 
 
Title IMPACT 
Description Rapid calculation of ion mobility collision cross sections 
Type Of Material Improvements to research infrastructure 
Year Produced 2015 
Provided To Others? Yes  
Impact Published and downloaded 
 
Title NMR assay 
Description This project has enabled the development and optimisation of a novel NMR screening protocol for the assessment of plasma protein binding, which simultaneously gives an assessment both of the level and location of binding. This information is particularly valuable for the design of new antibacterial agents with lowered plasma protein binding, a characteristic widely believed to enhance the level of bioactivity. Moreover, it has permitted initial work to demonstrate the viability of a wholly novel drug delivery system. 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact Facilitated understanding a key aspect of antibacterial drug discovery 
 
Title PULSAR 
Description Correlates unfolding with stability 
Type Of Material Improvements to research infrastructure 
Year Produced 2015 
Provided To Others? Yes  
Impact Published and downloaded 
 
Title adenovirus-based vaccine technology 
Description . Our adenovirus-based vaccine technology is the first vaccine to our knowledge that uses human cells as the expression system for an outer membrane protein from extracellular bacteria, using the adjuvant properties of a viral vector. This is innovative as bacterial outer membrane proteins might not be expected to fold properly or to undergo the correct post-translational modifications in a mammalian cell, and our findings with a MenB antigen are innovative and promising. 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact Progress to GMP for phase I study 
 
Description A novel vaccine for broad protection against meningococcal disease: selection of the optimal product composition for a phase I clinical trial 
Organisation Children's Hospital Oakland Research Institute (CHORI)
Country United States 
Sector Hospitals 
PI Contribution We established a fruitful and successful collaboration with P. Beernink at CHORI, Oakland, USA. We have provided expertise in vaccine development
Collaborator Contribution Our partner has provided sequences for proteins to be included in a vaccine candidate
Impact Potential for patents and publications
Start Year 2014
 
Description Antibacterial bioassays 
Organisation Sealife Pharma
Country Austria 
Sector Private 
PI Contribution Supply of new chemical entities
Collaborator Contribution Supply of antibacterial bioassays
Impact Data not finalised yet
Start Year 2014
 
Description BP project 
Organisation National Institute for Biological Standards and Control (NIBSC)
Country United Kingdom 
Sector Public 
PI Contribution Concept, design and production of novel vaccine candidates against BP
Collaborator Contribution Expertise in measuring immune response to BP vaccines, and efficacy in models
Impact Application for joint D.Phil studentship
Start Year 2016
 
Description Clinical Interpretation of SWAS 
Organisation University of Auckland
Department Faculty of Medical and Health Sciences
Country New Zealand 
Sector Academic/University 
PI Contribution We identified slow wave activity saturation (SWAS), generated the Bayesian model to determine whether an individual had achieved SWAS and applied this to our experimental data.
Collaborator Contribution Professor Jamie Sleigh, a world leader in electroencephalography under anaesthesia research, provided clinical EEG datasets acquired under surgical anaesthesia that allowed us to test and refine the SWAS Bayesian modelling in the clinical environment.
Impact We are preparing a paper for submission to a high-impact anaesthetic journal in the next month. The collaboration is multi-disciplinary covering the fields of neuroscience and clinical anaesthesia.
Start Year 2014
 
Description Collaboration on vaccine development against Coxiella 
Organisation Massachusetts General Hospital
Country United States 
Sector Hospitals 
PI Contribution Expertise in vaccine development against bacterial species, and in preclinical vacinology
Collaborator Contribution The partner designed the project, obtained funding, designed novel antigen targets and leads the scientific development with multiple partners
Impact Too early in the research
Start Year 2018
 
Description Collaboration on vaccine development against another Neisseria specie 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution Our experience in Neisseria meningitidis vaccine development and in working with a Neisseria specie in the laboratory (design, production, immunogenicity studies in animals and analysis of protective effect, outer membrane production)
Collaborator Contribution The partner Prof. C M designed and conceived a project, secrued funding and led further grant applications.
Impact Grant application to Bactivac, successful Grant application to Welcome trust, result pending
Start Year 2018
 
Description Improvement of antigen design 
Organisation Children's Hospital Oakland Research Institute (CHORI)
Country United States 
Sector Hospitals 
PI Contribution Confidential
Collaborator Contribution Confidential
Impact Confidential
Start Year 2014
 
Description Industrial collaboration 
Organisation Evotec
Country Germany 
Sector Private 
PI Contribution Supply of new chemical entities
Collaborator Contribution Supply of bioassay and expertise
Impact No finalised outcomes yet
Start Year 2014
 
Description Novel bivalent vaccine to prevent both Salmonella Typhi and Paratyphi infections 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution We have an expertise in preclinical vaccinology and designed and proposed the project and methodologies.
Collaborator Contribution Our partner has demonstrated that T-cells are induced during acute typhoid and paratyphoid fever in humans against the target antigen that we are proposing (Napolitani et al., manuscript in preparation). The partner will help in characterising the response induced by the vaccine.
Impact The partner provided data that support the project and the grant application.
Start Year 2017
 
Description Preclinical evaluation of a vaccine for Psoriasis 
Organisation University of Dundee
Department College of Medicine, Dentistry & Nursing
Country United Kingdom 
Sector Academic/University 
PI Contribution Discussion and design of experiments Provision of vaccine and related materials for preclinical studies
Collaborator Contribution Performed experiments - Preclinical studies and analysis of outcomes
Impact Publication of a review article Co-application for further funding Formed a new company - HealVax GmbH, currently seeking investment to fund GMP manufacture and phase I clinical trial.
Start Year 2015
 
Description Providing standards 
Organisation National Institute for Biological Standards and Control (NIBSC)
Country United Kingdom 
Sector Public 
PI Contribution Capacity and running of a clinical trial on meningococcal vaccines
Collaborator Contribution Proposed and support judicious addition to a clinical trial
Impact In progress, multi-disciplinary (immunology, assay development and standardisation)
Start Year 2017
 
Description Public health England for YP project 
Organisation Public Health England
Department Public Health England Porton Down
Country United Kingdom 
Sector Public 
PI Contribution Development of a novel vaccine based on the the expertise developed during this grant.
Collaborator Contribution Capacity to assess the functionality and efficacy of the vaccine candidate
Impact Funding obtained for clinical development of the new vaccine
Start Year 2017
 
Description Vector impact on innate T cells 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution Provide vaccine candidates and models to address fundamental immunology questions
Collaborator Contribution Provide expertise in fundamental immunology of innate T cells in relation to a vaccine modality
Impact In progress
Start Year 2017
 
Title Microdetect 
Description Microstructural brain changes for diagnosis of cognitive disorders. This is an invention intended for application in medical imaging, particularly MRI. The invention relates to methods of assessing or obtaining an indication of the presence of a cognitive disorder by analysing microstructural changes in regions of the brain. The invention particularly relates to methods of assessing or obtaining an indication of the presence of types of dementia, for example Alzheimer's disease, by analysing changes in minicolumns in regions or layers of the cortex of the brain or of the whole brain. 
IP Reference WO2016162682 
Protection Patent application published
Year Protection Granted 2016
Licensed No
Impact This IP will form a central part of a spin-out company that we expect to form in the next few months.
 
Title Investigating a new Vaccine against Meningitis B in Oxford (VAMBOX) 
Description This is a Phase I/IIa single-site dose-escalation clinical trial to test the safety and immunogenicity of a new vaccine against capsular group B meningococcal disease (MenB). It will be administered alone and following primary immunization with Bexsero, an existing licensed vaccine currently in the UK immunisation schedule for babies. We have started recruiting clinical trial volunteers and are in the process of screening our first participants. 
Type Therapeutic Intervention - Vaccines
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2018
Development Status Under active development/distribution
Impact Work in progress. 
URL http://trials.ovg.ox.ac.uk/trials/vambox
 
Title Cortical high intensity profile segmentation for MRI 
Description A novel software programme using the FSL platform was developed with collaborators in fMRIB for use in this analysis 
Type Of Technology Software 
Year Produced 2014 
Impact This software forms part of a patent that has been filed 
 
Company Name Oxford Antibiotics 
Description Antibacterial drug discovery 
Year Established 2017 
Impact None at this stage (too early), but in active discussion with industry and investors to map future directions
 
Description 'Can we make rabies history?' - Rabies elimination symposium at American Society of Tropical Medicine and Hygiene 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Alexander Douglas (award PI) organised a symposium about rabies control and elimination at the American Society for Tropical Medicine & Hygiene, New Orleans, October 2018, inviting speakers from Scotland, Kenya and Peru.

This was attended by around 50 people drawn from diverse backgrounds, with additional attendance via web-streaming / web archive- the meeting audience is broad, including public health practitioners, veterinarians, pharmaceutical industry personnel, non-governmental funders and press, and is the largest international meeting relating to global health. This was the first time a session about rabies has been organised at the meeting for several years- the key aim of the symposium was to raise the profile of rabies as a major public health problem and an important and neglected area for research and policy development.
Year(s) Of Engagement Activity 2018
 
Description Alports Syndrome International Workshop (2015) 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Presentation to ~150 people attending international workshop on Alports syndrome. Individuals included patients, carers and scientific researchers. Introduced new therapeutic concepts. Wide ranging discussions followed.
Year(s) Of Engagement Activity 2015
 
Description Antruk 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Establishement of ANTRUK
Year(s) Of Engagement Activity 2015
URL http://www.antibioticresearch.org.uk/
 
Description Attendee and Speaker at ACCESS conference 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Recent data was presented to the ACCESS group - Anesthesiologists concerned with Cognition, Emergence, Sedation and Sleep - to update the audience on progress made towards understanding brain activity alterations on induction and emergence from general anaesthesia.
Year(s) Of Engagement Activity 2016
 
Description BBC Radio 4 broadcast an exploration into this new understanding of psychiatric disorders earlier this year: The Inflamed Mind 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact BBC Radio 4 broadcast an exploration into this new understanding of psychiatric disorders earlier this year: The Inflamed Mind.
Year(s) Of Engagement Activity 2016
URL http://www.bbc.co.uk/programmes/b07pj2pw
 
Description BBC World Service - World Have Your Say - 2017/03/03 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact BBC World Service Discussion Programme regarding gene therapy in general, specially the use of lentiviral vectors and the correction of sickle cell anaemia.
Year(s) Of Engagement Activity 2017
URL http://www.bbc.co.uk/programmes/p04tv5n9
 
Description Brain Awareness public engagement event 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact A public engagement activities event at the History of Science Museum in Oxford. This was attended by members of the general public. It was free entry and many attendees were international visitors. The public were invited to look through microscopes at histological slides of human brain tissue (all confirmed ethical approval) and discuss what they could see. This was particularly appealing to a group of boys (age 7-11) visiting from Poland. But it also engaged some carers and relatives of people with dementia. In addition, a computer game had been developed by Dr Chance to engage youngsters with the neuroscience of Alzheimer's disease. Playing a fictional character 'shrunk to the size of a cell' the 1 or 2 players descended through the 'cortex' combating mutant tau and avoiding amyloid plaques in order to find stem cells in the sub-ventricular zone and transport them to the hippocampus to rewire into memory circuits. This was played enthusiastically by groups of girls and boys. One little boy's father requested access to the game for his son who returned later in the day in order to complete it. (Unfortunately it was not possible to distrbute the game).
Year(s) Of Engagement Activity 2016
 
Description Cafe Scientific Talk (Bradfield College 2015) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact Science discussion evenning event at Bradfield College. Wide ranging audience from school children to CF care givers and relatives. Talk stimulated extensive discussion and questions.
Year(s) Of Engagement Activity 2015
 
Description Dessimination: Neurosciences Grand Round, John Radcliffe Hospital, Oxford. April 2015 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Psychiatric channelopathies - Neurosciences Grand Round, John Radcliffe Hospital April 2015
Year(s) Of Engagement Activity 2015
 
Description Global health security (Welcome Trust) 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact to take part in a filming event with the Wellcome Trust. The event is being run/coordinated with Barry Gibb who is a scientific multimedia producer for the WT.
The event is centred around a computer game called The Last of Us. The game is based on a pandemic which has infected 60% of humanity in several months. They would like our input for a 'vaccine' discussion. The game will be used as the fiction starting point for discussion.
Year(s) Of Engagement Activity 2016
URL https://mosaicscience.com/outbreak
 
Description Guest Speaker at Genome Editing conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Highlighting Viral and Non-Viral Gene Therapy for Cystic Fibrosis
Year(s) Of Engagement Activity 2017
 
Description Guest speaker at CF Conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Presentation to conference on Emerging gene therapies for cystic fibrosis'
Year(s) Of Engagement Activity 2017
 
Description Guest speaker at CFF Research Conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Made a presentation on Sendai Virus Pseudotyped Lentiviral Vectors to conference members
Year(s) Of Engagement Activity 2017
 
Description Immunisation Seminar 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Presentation of the project and its status to nurses attending the yearly Immunisation Seminar organized by the oxford Vaccine Group
Year(s) Of Engagement Activity 2017
 
Description Invited seminar at Oxford Centre for Human Brain Activity 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Discussion of the current understanding of the effects of anaesthesia on brain function.
Year(s) Of Engagement Activity 2015
 
Description Keynote address, Encephalitis Society Professional Seminar 2015, London 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Keynote address: What do psychiatrists have to offer in the management of Augoimmune Encephalitis
Year(s) Of Engagement Activity 2015
URL http://www.encephalitis.info/files/2714/4596/2037/Prof_seminar_2015_WEB.pdf
 
Description Oxford Sciences Innovation Life Sciences Event 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Presentation of MRC CiC funded project on Slow wave activity saturation (SWAS) as a marker of depth of anaesthesia at local event for previous awardees and future applicants.
Year(s) Of Engagement Activity 2015
 
Description Oxford University Hospitals NHS Foundation Trust Audit Meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact I gave the University lecture at the Nuffield Department of Anaesthesia Audit on "Anaesthesia and Brain Function" to the practising anaesthetists within the local NHS Trust. It was described as the "most clinically relevant lecture in years" and "potentially ground breaking" research.
Year(s) Of Engagement Activity 2015
 
Description Participation in a television programme on BBC Two - Trust Me, I'm a Doctor. A special programme focussing on Mental Health 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact In the relevant section of the TV programme - "Could some mental health conditions be caused by an immune malfunction" I explained that some patients who exhibit classic symptoms of psychosis may not actually have a psychiatric condition, but a rare form of encephalitis and that the biological cause for this condition is now increasingly recognized by psychiatrists and neurosurgeons. Patients have been successfully treated with immunotherapy, which removes the rogue antibodies from the patient's blood. This treatment has led to patients making a dramatic recovery. I also described my current research investigating the prevalence of pathogenic antibodies in psychosis and its subsequent treatment. This was followed by a large number of enquiries from members of the public both nationally and internationally.
Year(s) Of Engagement Activity 2017
URL http://www.bbc.co.uk/programmes/articles/4dbMnJVnLBM9Qqp8rzKD4s3/could-some-mental-health-conditions...
 
Description Presentation and Cambridge Neuroscience Seminar 2017 - The Inflamed Brain - 21 March 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Plenary "The Autoimmune basis of Psychosis - challenges and controversies
Year(s) Of Engagement Activity 2017
URL http://www.neuroscience.cam.ac.uk/events/event.php?permalink=dbbbdfb739#plenary
 
Description Presentation at British Journal of Anaesthesia Research Forum 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Presented outcome of work completed on award to anaesthetists - potential end users. It was observed to be a big step towards individualised depth of anaesthesia monitoring.
Year(s) Of Engagement Activity 2017
 
Description Presentation at the 6th European Conference on Schizophrenia Research (ECSR) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Symposium presentation entitled: "The diagnosis and management of autoimmune encephalitis in psychiatric settings" at the 6th European Conference on Schizophrenia Research (ECSR), 24/11/2016
Year(s) Of Engagement Activity 2016
URL http://www.cpo-media.net/DGPPN/2016/Programm/HTML/files/assets/common/downloads/publication.pdf
 
Description Presentation to Rethink Mental Illness charity, Harrogate May 2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Presentation to Rethink Mental Illness charity in Harrogate, May 2015. Title: Brains on Fire.
Year(s) Of Engagement Activity 2015
 
Description Presentation to Urgent Care Research Conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Targeted clinicians and researchers involved with NIHR Clinical Research Network Thames Valley and South Midlands
Year(s) Of Engagement Activity 2016
 
Description Presentation: The prevalence of antibodies against neuronal cell surface targets in acute first episode psychosis, 15th International Congress on Schizophrenia Research' in Colorado Springs, Colorado, USA 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact This was a plenary session attended by academics and clinicians. Members of the audience remarked they were more convinced by the research presented in this session than had been heard previously.
Year(s) Of Engagement Activity 2015
 
Description Presentations to psychiatric teams: January - Reading, February - Oxford, March - Buckinghamshire, May - Swindon, June - Chippenham 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Antibodies and psychosis - what psychiatrists need to know - presentations to psychiatric teams: Reading Jan 2015, Oxford Feb 2015, Buckinghamshire March 2015, Swindon May 2015, Chippenham June 2015
Year(s) Of Engagement Activity 2015
 
Description Public Lecture 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? Yes
Geographic Reach Regional
Primary Audience Schools
Results and Impact Lecture initiated questions on working in STEM subjects

Considerable interest from talented students to pursue career in research, particularly Oxford
Year(s) Of Engagement Activity 2014
 
Description Research Meeting, MRC HQ London 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Meeting of potential investigators (psychiatrists and neurologists) to set up a network across England to seek out people with antibody-mediated psychosis and then offer them the change to be in a randomised controlled trial, to test the pathogenicity of these antibodies, using IVIG and rituximab.
Year(s) Of Engagement Activity 2015
 
Description Symposium speaker at British Neuroscience Association Festival of Neuroscience 2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Presentation detailing how brain activity in altered physiological states such as anaesthesia and pain could be quantified using functional imaging to an audience of ~100 UK neuroscientists.
Year(s) Of Engagement Activity 2015
 
Description Teaching/Science Session: Channelopathies: An open and shut case? Psychiatric channelopathies at Association of British Neurologists Annual Meeting, Harrogate 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Teaching/Science Session: Channelopathies: An open and shut case? Psychiatric channelopathies
Year(s) Of Engagement Activity 2015
URL http://www.theabn.org/media/docs/Meetings/2015%20ABN%20Harrogate%20draft%20programme_28.pdf